[클리니컬 히스토리] SK바사, PCV21 비용구간 대안 '정책차입'

SK Bioscience's acquisition of the National Growth Fund marks a significant shift in government support, moving beyond infrastructure to funding late-stage clinical trials for blockbuster vaccine candidates. By securing low-interest debt instead of equity, the company maintains shareholder value while aggressively pursuing the $12 billion pneumococcal vaccine market alongside Sanofi. This move sets a precedent for how large-scale policy finance can de-risk the commercialization of high-stakes biopharmaceuticals.